We currently don't have sufficient analyst coverage to forecast growth and revenue for Beacon Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth
16.2%
Revenue growth rate
n/a
Future return on equity
n/a
Analyst coverage
None
Last updated
n/a
Recent future growth updates
No updates
Recent updates
In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as Beacon Pharmaceuticals has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
DSE:BEACONPHAR - Analysts future estimates and past financials data (BDT Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2026
15,565
1,457
1,493
2,525
N/A
12/31/2025
14,785
1,240
726
1,644
N/A
9/30/2025
13,851
1,132
818
1,676
N/A
6/30/2025
12,543
947
777
1,600
N/A
3/31/2025
11,960
837
1,891
2,785
N/A
12/31/2024
11,579
570
1,490
1,834
N/A
9/30/2024
11,184
512
-494
351
N/A
6/30/2024
10,702
521
-1,300
-180
N/A
3/31/2024
9,893
466
-3,559
-1,622
N/A
12/31/2023
9,402
662
-1,817
-193
N/A
9/30/2023
8,812
651
-697
767
N/A
6/30/2023
8,510
510
-1,193
621
N/A
3/31/2023
8,190
699
-743
1,351
N/A
12/31/2022
7,887
936
-930
1,484
N/A
9/30/2022
7,774
812
-1,083
1,238
N/A
6/30/2022
8,023
935
-637
1,082
N/A
3/31/2022
6,976
936
-479
708
N/A
12/31/2021
7,733
1,170
-551
180
N/A
9/30/2021
7,839
1,158
-226
203
N/A
6/30/2021
7,121
863
-117
197
N/A
3/31/2021
7,719
1,007
-59
321
N/A
12/31/2020
6,493
603
-94
249
N/A
9/30/2020
5,797
396
-228
93
N/A
6/30/2020
5,591
381
-23
291
N/A
3/31/2020
5,368
115
-399
-235
N/A
12/31/2019
5,155
104
N/A
146
N/A
9/30/2019
4,919
121
N/A
289
N/A
6/30/2019
4,647
118
N/A
220
N/A
3/31/2019
4,564
176
N/A
28
N/A
12/31/2018
4,281
162
N/A
75
N/A
9/30/2018
3,917
142
N/A
173
N/A
6/30/2018
3,761
126
N/A
300
N/A
3/31/2018
3,295
122
N/A
1,049
N/A
12/31/2017
3,259
118
N/A
944
N/A
9/30/2017
3,082
114
N/A
919
N/A
6/30/2017
2,948
104
N/A
981
N/A
3/31/2017
3,004
89
N/A
776
N/A
12/31/2016
2,764
67
N/A
504
N/A
9/30/2016
2,640
63
N/A
739
N/A
6/30/2016
2,492
61
N/A
558
N/A
3/31/2016
2,279
58
N/A
208
N/A
12/31/2015
2,169
58
N/A
294
N/A
9/30/2015
2,128
43
N/A
-7
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BEACONPHAR's forecast earnings growth is above the savings rate (4.2%).
Earnings vs Market: Insufficient data to determine if BEACONPHAR's earnings are forecast to grow faster than the BD market
High Growth Earnings: Insufficient data to determine if BEACONPHAR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BEACONPHAR's revenue is forecast to grow faster than the BD market.
High Growth Revenue: Insufficient data to determine if BEACONPHAR's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BEACONPHAR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/06 18:45
End of Day Share Price
2026/07/06 00:00
Earnings
2026/03/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beacon Pharmaceuticals PLC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.